logo_5PR Krajowy Punkt Kontaktowy logo_IPPT

Strona KPK:






  Biuletyn CTI

  Sieć KPK



Jakość życia i zarządzanie żywymi zasobami



Structure of the thematic priorities of the fifth framework programme 1998-2002

First thematic programme:

Quality of Life and Management of Living Resources.

1. EC Framework Programme

1.1. First activity.

1.1.1. Quality of Life and Management of Living Resources.

1.1.1.-1. Key action Food, Nutrition and Health

1.1.1.-1.1 Development of safe and flexible and new and/or improved manufacturing processes and technologies

1.1.1.-1.1.1. Novel and improved biological raw materials for high quality food

1.1.1.-1.1.2. Advanced and optimised food technologies, packaging systems and process control

1.1.1.-1.1.3. Quality monitoring and traceability throughout the food chain

1.1.1.-1.2 Development of tests to detect and processes to eliminate infectious and toxic agents throughout the food chain

1.1.1.-1.2.1. Improved understanding and control of contamination conditions.

1.1.1.-1.2.2. Rapid detection tests for pathogens, xenobiotics and hormones.

1.1.1.-1.2.3. New and safer methods of food production and distribution.

1.1.1.-1.2.4. New methodologies for assessing microbial, chemical and allergenic risks and exposures.

1.1.1.-1.3. Research into the role of food in promoting and sustaining health

1.1.1.-1.3.1. Role and impact of food on physiological functions, physical and mental performance

1.1.1.-1.3.2. Particular nutritional needs of defined population groups.

1.1.1.-1.3.3. Links between diet and chronic diseases and disorders including the genetic factors involved.

1.1.1.-1.3.4. Consumer attitudes and reactions with regard to food products, food processing and labelling.

1.1.1.-2. Key action Control of Infectious Diseases

1.1.1.-2.1. Development of improved or novel mono-component, multi-component and combined vaccines

1.1.1.-2.1.1. Discovery phase and preclinical development of vaccines.

1.1.1.-2.1.2. Development of European networks for clinical and field trials of vaccines.

1.1.1.-2.1.3. Underlying mechanisms ("transdisease vaccinology")

1.1.1.-2.2. Strategies to identify and control infectious diseases

1.1.1.-2.2.1. Comprehensive approaches for the treatment of, and protection against, human and animal infectious diseases.

1.1.1.-2.2.2. Antimicrobial drug resistance and changes in virulence.

1.1.1.-2.2.3. Diagnostic tests for humans and animals.

1.1.1.-2.2.4. Risk assessment and transmission.

1.1.1.-2.3. Aspects of public health and care delivery systems

1.1.1.-2.3.1. Organisational and economic aspects of public health.

1.1.1.-2.3.2. Surveillance, monitoring and evaluation methodologies in prevention and cure.

1.1.1.-2.3.3. Methodologies for product safety surveillance in the market place.

1.1.1,-3. Key action The "Cell factory"

1.1.1.-3.1. New and innovative health-related processes and products

1.1.1.-3.1.1. Development of new diagnostics, therapeutic substances and strategies.

1.1.1.-3.1.2. New and improved technologies for biological productions.

1.1.1.-3.1.3. Novel in-vitro testing as alternatives to animal testing.

1.1.1.-3.2. Energy – efficient bioremediation and waste biotreatment processes

1.1.1.-3.2.1. New bioprocesses for preventing industrial pollution, treating, upgrading, and/or recycling bioaccumulable wastes and industrial by-products.

1.1.1.-3.2.2. Bioassays and biosensors.

1.1.1.-3.2.3. Biodegradation of recalcitrant chemicals.

1.1.1.-3.2.4. Biodiversity and ecological dynamics of natural and introduced populations.

1.1.1.-3.2.5. Development of methods and strategies to ensure the safety of new biomolecules or bioprocesses, and for the identification of recombinant organisms and their residues in the environment and their impact on human and animal health.

1.1.1.-3.3. New biological and biotechnological processes and products from cell factories

1.1.1.-3.3.1. Exploiting the cellular and molecular characteristics of organisms

1.1.1.-3.3.2. High value-added products and processes involving / derived from micro-organisms, plants and animals.

1.1.1.-3.3.3. Functional biomolecules and biocatalysts.

1.1.1.-3.3.4. Identification and sustainable use of metabolic and genetic diversity as a source of new valuable products.

1.1.1.-4. Key action Environment and Health

1.1.1.-4.1. Diseases and allergies related to or influenced by the environment, their prevention and treatment

1.1.1.-4.1.1. Analysis and quantification of the impact of environmental factors on human health.

1.1.1.-4.1.2. Assessment of the relative importance of, and the interactions between, factors impinging on health.

1.1.1.-4.1.3. Development of an integrated approach to risk management - taking into account environmental and public health aspects

1.1.1.-4.2. Diagnosis, risk assessment and risk management processes to reduce causes and harmful environmental health effects

1.1.1.-4.2.1. Development of methods to assess environmental hazards including mixed exposures, cumulative and low dose effects

1.1.1..4-2.2. Improvement of predictive toxicity testing and mechanism-based risk assessment consistent with the aim of the reduction and eventual replacement of animal testing.

1.1.1.-4.2.3. Improved methods and technologies for long and short-term exposure and effects assessment including bio-markers (and bio-indicators)of environmental exposure, and susceptibility to environmental agents.

1.1.1-5. Key action Sustainable Agriculture, Fisheries and Forestry

1.1.1.-5.1. New and sustainable systems of production, including breeding methods and exploitation in agriculture, fisheries and aquaculture

1.1.1.-5.1.1. Sustainable agriculture

1.1.1.-5.1.2. Sustainable fisheries and aquaculture

1.1.1.-5.2. The integrated production and exploitation of biological materials for non-food users

1.1.1.-5.2.1 Bulk chemicals (lubricants, paints, detergents, solvents)

1.1.1.-5.2.2 Non-wood fibre composites

1.1.1.-5.2.3 Bioplastics and biopolymers

1.1.1.-5.2.4 Speciality chemicals (biological control products, cosmetics, food ingredients, drugs and vaccines)

1.1.1.-5.2.5 Biofuels

1.1.1.-5.3. Sustainable and multi-purpose utilisation of forest resources; the integrated forestry-wood chain

1.1.1.-5.3.1 Multifunctional management of forests

1.1.1.-5.3.2 Strategies for the sustainable and multipurpose utilisation of forest resources; the forestry-wood chain

1.1.1.-5.4. Support for common policies – development of methods of control, surveillance and protection including protection of land and prevention of soil erosion. Pre-legislative research designed to provide a scientific basis for Community legislation.

1.1.1.-5.4.1 Community agriculture and the international context

1.1.1.-5.4.2 CAP measures and related activities including socio-economic aspects

1.1.1.-5.4.3 Monitoring and enforcement of the CFP

1.1.1.-5.4.4 Social and economic basis of the CFP

1.1.1.-5.5. New tools and models for the integrated and sustainable development of rural and other relevant areas

1.1.1.-5.5.1 Analysing rural situations, changes and trends

1.1.1.-5.5.2 Conceptualising integrated development of rural and other relevant areas

1.1.1.-5.5.3 Assessing rural and coastal development performance and policies

1.1.1.-6. Key action The Ageing Population and Disabilities

1.1.1.-6.1. Age-related illnesses and health problems

1.1.1.-6.2. Determinants of health ageing

1.1.1.-6.3. Democraphy and epidemiology of ageing

1.1.1.-6.4. Coping with functional limitations in old age

1.1.1.-6.5. Health and social care services to older people

1.1.1.-7 Chronic and degenerative diseases, cancer, diabetes, cardivascular diseases and rare diseases

1.1.1.-7.1. Aetiology, pathophysiology, progress and outcome of diseases

1.1.1.-7.2. Evaluation of therapies through multinational, large scale studies/trials

1.1.1.-7.3. Optimised use of databases, registries, reagents and sample banks

1.1.1.-8. Research into genomes and diseases of genetic origin

1.1.1.-8.1. Interpretation of the meaning of genome information

1.1.1.-8.2. Acquisition of, access to and interpretation of genomic and functional data

1.1.1.-8.3 Development of novel expression systems, model organisms, mutant, transgenic and hybrid organisms

1.1.1.-8.4. Development and application of underpinning biochemistry, biophysical, statistical and computational approaches

1.1.1.-9. Neurosciences

1.1.1.-9.1. Cell communication including mechanisms of learning and memory

1.1.1.-9.2. Brain theories, computational neuroscience and neuroinformatics

1.1.1.-9.3. Brain development, disorders and repair and their clinical, epidemiological and social implications

1.1.1.-9.4. Behaviour, cognition and functional mapping of the brain

1.1.1.-10. Public health and health services research

1.1.1.-10.1. Public health research, health services research and health and safety

1.1.1.-10.2. Fighting drug related problems

1.1.1.-11. Research relating to the persons with disabilities

1.1.1.-11.1. Determinants of impairment, disability and handicap

1.1.1.-11.2. Methodologies for the assessment of quality of life

1.1.1.-11.3. Innovative technological research for the rehabilitation and assistance

1.1.1.-11.4. Health and social care delivery

1.1.1.-12. Biomedical ethics and bioethics in the context of respect for fundamental human values

1.1.1.-12.1. Ethical aspects of scientific and technological developments

1.1.1.-12.2. Ethical framework for life sciences

1.1.1.-12.3. Public policies, law and bioethics

1.1.1.-12.4. Bioethics infrastructures and methodologies

1.1.1.-13. Socio-economic aspects of life sciences and technologies

1.1.1.-13.1. Development of indicators and knowledge bases relevant to public policy decision making and regulation; technology evaluation and assessment, public perception and information

1.1.1.-13.2. Analysis of the links between life sciences and technologies and policies in the field of industry, agriculture, fisheries, food, environment, sustainable development, public health

1.1.1.-13.3. Analysis of social and economic driving forces and of barriers to development and exploitation of new opportunities in the bioindustries

1.1.1.-14. Support for research infrastructures

1.1.1.-14.1. Biological collections

1.1.1.-14.2. Biological information resources

1.1.1.-14.3. Clinical research facilities

1.1.1.-14.4. Pre-clinical research facilities

1.1.1.-14.5. Facilities for aquaculture and fishery research


Strona QOL:



Cele i








Strona główna Ostatnia modyfikacja:  11.01.2000r. Koordynator 1PT:  
Anna Pytko